• Explore /
  • Poster
  • / Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.

Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.

Abstract Poster

Authors

null

Mitesh J. Borad

Mayo Clinic, Scottsdale, AZ

Mitesh J. Borad , Sarah Lindsey Davis , Maeve Aine Lowery , Christine F. Lihou , Ghassan K. Abou-Alfa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02924376

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4145)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4145

Abstract #

TPS4145

Poster Bd #

130a

Abstract Disclosures

Similar Posters

First Author: Severine Guiu Lahaye

First Author: Mitesh J. Borad

First Author: Zachary Risch

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Real-world use of pemigatinib (pemi) for cholangiocarcinoma (CCA) among racial and ethnic minorities in the United States.

Real-world use of pemigatinib (pemi) for cholangiocarcinoma (CCA) among racial and ethnic minorities in the United States.

First Author: Richard D. Kim